Quantcast
Last updated on April 18, 2014 at 7:29 EDT

Latest CD134 Stories

2013-02-04 08:25:10

MUMBAI, India, February 4, 2013 /PRNewswire/ -- - GBR 830 is the first antagonistic antibody targeting OX40 and is a potential Global First-in-class molecule - OX40, also known as CD134, plays a key role in T-cell mediated autoimmune disorders. Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel...

2012-12-07 08:24:19

Deal to develop MD Anderson discovery draws on expertise of Institute for Applied Cancer Science HOUSTON, Dec. 7, 2012 /PRNewswire-USNewswire/ -- The University of Texas MD Anderson Cancer Center and GlaxoSmithKline (GSK) have signed a research collaboration and license agreement to develop new therapeutic antibodies that promote an immune system attack against cancer. Under terms of the agreement, MD Anderson grants GSK exclusive worldwide rights to develop and commercialize the...

2012-10-24 23:54:10

Cancers arise in the body all the time. Most are nipped in the bud by the immune response, not least by its T cells, which detect telltale molecular markers–or antigens–on cancer cells and destroy them before they grow into tumors. Cancer cells, for their part, evolve constantly to evade such assassination. Those that succeed become full-blown malignancies. Yet, given the right sort of help, the immune system can destroy even these entrenched tumors. In the October 22nd issue...